Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).

Massimo, A., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., et al. (2017). Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program. CLINICAL INFECTIOUS DISEASES, 64(5), 680-683 [10.1093/cid/ciw846].

Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program

DE LUCA, ANDREA;Puoti, M;GORI, ANDREA;
2017

Abstract

Patients coinfected with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are at high risk of liver disease progression. We report a favorable safety profile and SVR12 rates of 96.7% among HIV/HCV coinfected patients participating in an Italian compassionate-use program of ombitasvir/ paritaprevir/ritonavir + dasabuvir (OBV/PTV/r + DSV) ± ribavirin (RBV).
Articolo in rivista - Articolo scientifico
Anti-HCV therapy; Antiviral therapy; DAA; HIV/HCV coinfection; IFN-free;
DAA; HIV/HCV co-infection; IFN-free; anti-HCV therapy; antiviral therapy
English
680
683
4
Massimo, A., Teti, E., Antinori, A., Milazzoi, L., Sollima, S., Rizzardini, G., et al. (2017). Ombitasvir/paritaprevir/ritonavir and dasabuvir combination treatment in patients with HIV/HCV coinfection: Results of an Italian compassionate use program. CLINICAL INFECTIOUS DISEASES, 64(5), 680-683 [10.1093/cid/ciw846].
Massimo, A; Teti, E; Antinori, A; Milazzoi, L; Sollima, S; Rizzardini, G; Di Biagio, A; Saracino, A; Bruno, R; Borghi, V; DE LUCA, A; Cattelan, A; Hasson, H; Taliani, G; Monforte, A; Mastroianni, C; Di Perri, G; Bigoni, S; Puoti, M; Spinetti, A; Gori, A; Boffa, N; Bruno, C; Giacometti, A; Parruti, G; Vullo, V; Chirianni, A; Pennica, A; Pasquazzi, C; Segala, D; Sarmati, L
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/10281/140842
Citazioni
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 9
Social impact